Recent Updates
Recently added Catalysts

Atomoxetine

Phase 3

Attention Deficit Hyperactivity Disorder | Small molecule | Psychiatry |Eli Lilly and Company|Last Updated: Aug 31, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials24
Total Enrollment7,508

FDA Designations

No designations recorded

Clinical trial landscape

Atomoxetine · 30 trials · 8 indications

Phase 3 21Phase 2 7Phase 1 2
NCT00969618A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity Disorder
COMPLETED211 Analytics
NCT00962104Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity DisorderAttention Deficit Hyperactivity Disorder
COMPLETED391 Analytics
NCT00700427A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder
COMPLETED2,017 Analytics
NCT00568685Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder
COMPLETED153 Analytics
NCT00447278A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and AdolescentsAttention Deficit Hyperactivity Disorder
COMPLETED399 Analytics
NCT00320528Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Disorder With Hyperactivity
COMPLETED269 Analytics
NCT00191945Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder
COMPLETED151 Analytics
NCT00191386Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)Attention Deficit Hyperactivity Disorder
COMPLETED228 Analytics
NCT00191542Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and AdolescentsAttention Deficit Hyperactivity Disorder
COMPLETED100 Analytics
NCT00191737An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity DisorderAttention Deficit Hyperactivity Disorder
COMPLETED147 Analytics
PHASE3COMPLETED
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With HyperactivityUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
Attention Deficit Hyperactivity DisorderUnlock trial analytics
PHASE3COMPLETED
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Adverse Events Leading to Discontinuation
Baseline through 48 weeks
Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score up to 10 Weeks
Baseline, up to 10 weeks

CAARS-Inv:SV is a scale that assesses symptom severity over past week. Total ADHD symptom score consisted of 18 items (sum of inattention \[9 items, range: 0-27\] and hyperactivity-impulsivity \[9 items, range: 0-27\] subscales) using a 4-point scale (0=not at all/never to 3=very much/very frequently) for total score range of 0 to 54. Higher scores indicate greater impairment.

Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period
Baseline (Week 24) up to Week 49

Conners' Adult ADHD Rating Scale-Investigator Rated:Screening Version (CAARS-Inv:SV); 30-item scale (3 subscales): inattention, hyperactivity/impulsivity (9 items each), ADHD Index (12 items). Each item is scored 0 (not at all/never) to 3 (very much/very frequently). Total ADHD symptoms score (SS)=inattention+hyperactivity/impulsivity (range:0-54). Higher score=more impairment. Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) measures participant's overall severity of ADHD symptoms and scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Maintenance of response during the randomized withdrawal phase was a reduction of ≥30% in the baseline CAARS-Inv:SV Total ADHD SS and a CGI-ADHD-S score ≤3. Participants had to continuously meet the response criteria, except for 1 excursion after assessment at Week 24 through Week 37 and 1 other excursion after assessment at Week 37 through Week 49. Excursions were not permitted at 2 consecutive visits.

Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score
Baseline, Day 42

Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 none/never or rarely) to 3 (severe/very often). Total scores range from 0 (no symptoms) to 54 (highly symptomatic).

Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain
Baseline, 6 months

CHIP-CE PRF: parent rated assessment of a child's health status/level of functioning. The achievement domain describes developmentally appropriate role functioning in school and with peers. The majority of items assess frequency of activities or feelings using a 5-point response format (1=never, 5=always). Standard scores (T-scores) were established, with all domains and subdomains having a mean score of 50 and standard deviation of 10. Normative range is 40 to 60. Higher scores indicate better health and lower scores indicate worse health.

Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain
Baseline, 12 Weeks

Parent-rated assessment of a child's health status and level of functioning. It consists of 76 items. The majority of items assess frequency of activities or feelings using a five-point response format (for example, 'how good is your child at making friends?' 1=never, 5=always). Standard scores (t-value) were established, with all domains and subdomains having a mean score of 50 and standard deviation of 10. Standard scores are expressed in standard deviation units. Achievement Domain Range = -3.1 to 67.7. Higher scores mean greater health or level of functioning in achievement.

Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint
Week 12

Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total Scores range from 0 to 54.

Number of Participants With Adverse Events for Long Term Safety and Tolerability
Baseline through 4 years

Details on the actual adverse events are presented in the Reported Adverse Events Section.

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall
functioning of patients with ADHD as measured by the mean change in the total score of the Child Health and Illness Profile-Child Edition-Parent form (CHIP-CE-Parent form) domain Achievement.
Global Impression of Perceived Difficulties (GIPD) scale at baseline, Week 8 and Week 24
Change From Baseline to 8 Week Endpoint in Swanson, Nolan and Pelham Questionnaire (SNAP-IV): Attention-Deficit/Hyperactivity Disorder (ADHD) Subscale
Visit 8 (baseline) and Visit 14 (8 weeks)

Items from the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for ADHD are included for the two subsets of symptoms: inattention (items #1-#9) and hyperactivity/impulsivity (items #11-#19). The SNAP-IV is based on a 0 (not at all) to 3 (very much) rating scale. Total subscale scores range from 0 to 54.

Efficacy of atomoxetine administered as a single-daily dose with placebo in Russian children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
To test whether atomoxetine given for 10 weeks is superior to standard current therapy as measured by CHIP-CE (Child Health and Illness Profile - Child Edition)
The primary objective of this study is to assess the correlation of change from baseline to one year in ADHD symptoms as measured by the Attention Deficit/Hyperactivity Disorder Rating Scale- IV-
Parent Version: Investigator Administered and Scored,
total score, with change from baseline in academic achievement of medication-naive patients treated with atomoxetine at one year as measured by the total
of the composite scores of the broad reading, broad math, and broad language subtests of the Woodcock-Johnson Tests of Achievement (WJII)
Test the hypothesis that atomoxetine administered as a single-daily dose provides superior efficacy compared with placebo in Taiwanese children and adolescents with ADHD
Assess the safety of atomoxetine and placebo compared to atomoxetine and methylphenidate in children aged 6 through 12 years with ADHD who have been identified as stimulant non-responders and have been exposed to acute treatment of atomoxetine.
Test the hypothesis that atomoxetine hydrochloride is non-inferior to methylphenidate hydrochloride in improving ADHD symptoms following an approximately 8-week period of double blind treatment as assessed by a comparison of response rates
Mean reduction in ODD symptoms using the Swanson, Nolan and Pelham Rating Scale-Revised (SNAP-IV), atomoxetine vs placebo
over 8 weeks
Test whether patients treated with atomoxetine 1.2 mg/kg/day who have sub-optimal clinical responses and peak plasma atomoxetine levels no higher than 800 ng/mL will benefit from a dose increase to 2.4 mg/kg/day
Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study
Baseline through 5 years

Vital signs were assesed categorically using the term high for BP, high and low for pulse and temperature, or decreased for weight. For BP, high was an increase to a value above the 95th percentile of the National Institute of Health (NIH) values. For pulse, high was an increase of at least 25 beats per minute to at least 110, and low was a decrease of at least 20 beats per minute to at most 65 beats per minute. For temperature, high was an increase of at least 1 to 37.7 and low was a decrease of at least 1.3 to at most 35.6. Decrease in weight was marked by a reduction of at least 3.5%.

Change From Baseline to 5 Year Endpoint in BP
baseline, 5 years
Change From Baseline to 5 Year Endpoint in Pulse
baseline, 5 years
Change From Baseline to 5 Year Endpoint in Body Weight
baseline, 5 years
Change From Baseline to 5 Year Endpoint in Height
baseline, 5 years
Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile
baseline, 5 years

Patients were assessed for changes in weight, height, and BMI. BMI is an estimate of body fat based on body weight divided by height squared.

Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG)
baseline, 5 years

Patients were assessed for changes in ECG. The RR interval is the time duration between two consecutive R waves of the ECG. The QRS interval is the beginning of Q to the end of the S wave. The QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula.QTdat is the QT interval using a data specific correction method for children.

Change From Baseline to 5 Year Endpoint in Heart Rate
baseline, 5 years

Patients were assessed for changes in heart rate using electrocardiogram.

Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase)
baseline through 5 years

QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula. QTdat is the QT interval using a data specific correction method for children.

Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint)
baseline through 5 years

QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate. A corrected QT interval (QTc) has been corrected in order to aid interpretation. QTbz is the QT interval using Bazett's correction formula. QTfr is the QT interval using Fridericia's correction formula. QTdat is the QT interval using a data specific correction method for children. For Males: Normal is \<430 ms, Borderline is \>=430 ms and \<450 ms, Prolonged is \>=450 ms. For Females: Normal is \<450 ms, Borderline is \>=450 ms and \<470 ms, Prolonged is \>=470 ms.

Number of Participants With Abnormal Laboratory Analytes During the Study
baseline through 5 years

Standard reference ranges from Covance Laboratories were used in the determination of abnormal high and low values based on age and gender, where appropriate. Aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase (SGOT); units/liter (U/L); alanine aminotransferase (ALT); serum glutamic pyruvic transaminase (SGPT); millimoles/liter (mmol/L); grams/liter (g/L); micromoles/liter (umol/L); millimoles/liter-iron (mmol/L-Fe); trillion/liter (TI/L)or 10\^12 units/liter; Giga/liter (GI/L)or 10\^9 units/liter; femtoliters (fL); urinalysis (UA)

Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group
1 year through 5 years

Tanner Stage: I: no pubic hair at all (prepubertal Dominic state) II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum (males) or on the labia majora (females) III: hair becomes more coarse and curly, and begins to extend laterally IV: adult-like hair quality, extending across pubis but sparing medial thighs V: hair extends to medial surface of the thighs Age Groups: 1. age\<11.0 (female) and age\<12 (male) 2. 11=\<age\<12 (female) or 12\<=age\<13 (male) 3. 12=\<age\<15 (female) or 13=\<age\<15 (male) 4. age\>=15 (female and male)

% Urine Samples Negative for Cocaine
Urines were collected 3 times per week (e.g., Monday, Wednesday and Friday) for 12 weeks

Total % urine samples negative for benzoylecgonine over the 12-week trial

Discontinuations Due to Adverse Events (AE)
Baseline to 8 Weeks

The definition of a study adverse event was any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.

Conners' Adult Attention Rating Scale (CAARS)
There are two time points for this measure: baseline and after 4 weeks of treatment

The Conners' Adult Attention Rating Scale (CAARS) is one of the most frequently used self-rating measures for adult Attention Deficit Hyperactivity Disorder (ADHD) and was given as a self-report measure of attention. It has 66 items with each item ranging from 0 to 3 points. Higher total scores represent greater impairment. The outcome reported was change in score from baseline for each treatment arm.

Attention Composite Score
There are two time points for this measure: baseline and after 4 weeks of treatment

The attention composite comprises performance on Wechsler Adult Intelligence Scale III Symbol-Digit and Letter Number Sequencing Subtests, Trail Making Test Part A, computerized simple-choice reaction time, and computerized working memory (i.e., 2-Back). The composite score is the average combined z score for each test. Higher, positive values indicate better than average performance and negative and lower values indicate worse than average. The outcome reported was change in score from baseline for each treatment arm.

Executive Composite Score
There are two time points for this measure: baseline and after 4 weeks of treatment

The executive composite comprises performance on Trail Making Test Part B, Stroop Color and Word Test, and the Controlled Oral Word Association Test (i.e., Verbal Fluency). The composite score is the average combined z score for each test. Positive values indicate better than average performance and negative values worse than average. The outcome reported was change in score from baseline for each treatment arm.

Change of total score on ADHD RS-IV-JParent Version: Investigation-Administered and Scored
To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive
The primary objective of the study is to assess whether treatment with 1.8 mg/kg/day of atomoxetine will be safe and tolerable in a population of Japanese pediatric patients aged 6 through 18 years.
Maximum Observed Plasma Concentration (Cmax)
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, 12, 18, and 24 hours post dose

The Cmax values are based on the atomoxetine plasma concentration. The Least Squares (LS) Mean Value was based on treatment, period, group, and subject.

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)]
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, 12, 18, and 24 hours post dose

The AUC (0-tlast) is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (tlast) and is based on the atomoxetine plasma concentration. The Least Squares (LS) Mean Value was based on treatment, period, group, and subject.

Secondary Endpoints

Mean Change From Baseline to 48 Weeks Endpoint in the Conners' Adult Attention-Deficit Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version-Japanese (CAARS-Inv:SV-J)
Baseline, 48 weeks
Mean Change From Baseline to 48 Weeks Endpoint in the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life (AAQoL)-29 Scores
Baseline, 48 weeks
Mean Change From Baseline to 48 Weeks Endpoint in the Behavior Rating Inventory of Executive Function -Adult (BRIEF-A) Version: Self Report (BRIEF-A:Self Report )
Baseline, 48 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AtomoxetineEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)ACTIVE_COMPARATOR -
Atomoxetine 0.5 mg/kg/dayACTIVE_COMPARATOR -
Atomoxetine 1.2 mg/kg/dayACTIVE_COMPARATOR -
OESTACTIVE_COMPARATOROther Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
Pure ADHDEXPERIMENTALAttention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
ADHD+Internalizing DisordersEXPERIMENTALAttention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
ADHD+Externalizing DisordersEXPERIMENTALAttention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
AEXPERIMENTALAtomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
BPLACEBO_COMPARATORPlacebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
1EXPERIMENTALAtomoxetine
2PLACEBO_COMPARATORMatched Placebo
40 milligram twice a day atomoxetineEXPERIMENTALParticipants received 40 milligram twice a day atomoxetine for 4 weeks.
Twice a day matching placeboPLACEBO_COMPARATORParticipants received twice a day matching placebo for 4 weeks.
Atomoxetine Oral SolutionEXPERIMENTAL -
Atomoxetine Capsule FormulationACTIVE_COMPARATOR -

Interventions

NameTypeDescription
AtomoxetineDRUG40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
PlaceboDRUGTaken by mouth, once daily for 10 weeks.
atomoxetine hydrochlorideDRUGOral 40-100 mg/day
Other standard therapy for ADHDDRUGAny treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
atomoxetine 0.5 mg/kg/dayDRUGatomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
atomoxetine 1.2 mg/kg/dayDRUGatomoxetine 1.2 mg/kg/day QD, PO
atomoxetine 1.2-1.4 mg/kg/dayDRUGatomoxetine 1.2 - 1.4 mg/kg/day QD, PO
Methylphenidate HydrochlorideDRUG -
Matching PlaceboDRUGThis study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
olanzapineDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Patients who have completed the B4Z-JE-LYEE study (NCT00962104) and signed the Informed Consent Document (ICD). * Patients must have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including venipuncture and examinations, re...

Countries:JapanSouth KoreaTaiwanAustriaBelgiumFinlandFranceGermanyItalyNetherlandsPortugalSpainSwedenSwitzerlandUnited KingdomIrelandMexicoNorwayTurkey (Türkiye)RussiaCanadaUnited StatesChinaAustraliaDenmarkIsraelPuerto RicoSouth Africa
Unlock Eligibility Criteria

Frequently asked questions about Atomoxetine

What is Atomoxetine used for?

Atomoxetine is a small molecule being studied for use in Huntington Disease, Attention Deficit Hyperactivity Disorder, Substance Abuse, Schizophrenia, Alzheimer Disease, and Attention Deficit Disorder With Hyperactivity. It is in Phase 3 clinical development and is being developed by Eli Lilly and Company.

Who makes Atomoxetine?

Atomoxetine is being developed by Eli Lilly and Company, which trades under the ticker LLY. The drug is a small molecule in the psychiatry therapeutic area and is currently in Phase 3 clinical development.

What phase is Atomoxetine in?

Atomoxetine is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. It is being studied for multiple psychiatric conditions, including attention deficit hyperactivity disorder and Alzheimer disease.

What clinical trials is Atomoxetine in?

Atomoxetine has been studied in 24 clinical trials with a total enrollment of 7,508 participants. Examples include NCT00191009, a Phase 2 trial in Alzheimer Disease, and NCT00485628, a Phase 2 trial in Japanese children with ADHD. All 24 trials are completed.

Is Atomoxetine the same as Strattera?

Atomoxetine is also known by the brand name Strattera. It is a non-stimulant medication used in the treatment of attention deficit hyperactivity disorder. Eli Lilly and Company is the developer of this drug.